Tuberculosis (TB) Diagnostics Market Size, Share & Segmentation By Type (Culture-Based Diagnostics, Sputum Smear Microscopy, Rapid Molecular Diagnostics), By End User (Hospitals, Diagnostics, and Laboratories), By Regions and Forecast 2024-2031

Tuberculosis (TB) Diagnostics Market Report Scope & Overview:

Tuberculosis (TB) Diagnostics Market size was valued at USD 2.16 billion in 2023 and is expected to reach USD 3.60 billion By 2031 and grow at a CAGR of 6.60% over the forecast period of 2024-2031.

The Tuberculosis (TB) Diagnostics Market refers to the market for diagnostic equipment and tests used in the detection and diagnosis of tuberculosis, a contagious bacterial infection caused by Mycobacterium tuberculosis. TB diagnostics serve a critical role in identifying active TB cases, assessing Product response, and restricting the spread of the illness. The market covers a range of diagnostic methods and products designed to identify TB infections. Sputum samples are examined under a microscope using a traditional diagnostic approach to look for the presence of TB germs. assays carried out on blood samples that look for antibodies produced in response to TB infection. Although frequently employed as screening tools, these tests have limitations in terms of accuracy and their inability to distinguish between latent and active infections.

Get More Information on Tuberculosis (TB) Diagnostics Market - Request Sample Report

The global incidence of TB, raising awareness of early diagnosis, technical improvements, and government attempts to combat the disease are some of the reasons driving the TB diagnostics market. The market is characterised by ongoing research and development projects to provide diagnostic technologies that are more precise, quick, and economical. In order to increase access to testing and early detection, efforts are being concentrated on point-of-care diagnostics that can be used in environments with limited resources. The TB diagnostics market has regional variations, with high-burden nations like India, China, and Sub-Saharan Africa having significant market potential due to the incidence of TB. However, the market is international in scope, and TB diagnostic technologies are being developed, produced, and used by healthcare organisations all over the world.

Market Dynamics:

• A serious worldwide health concern, tuberculosis has a high disease burden in many nations.

• Point-of-care the importance of TB diagnostics, which offer quick results at the point of care, is growing.

• International collaboration and partnerships.

Innovative TB diagnostic technologies are developed and commercialised as a result of partnerships between research institutes, diagnostic firms, and international health organisations. These collaborations extend the range of TB diagnosis choices by quickening the release of new diagnostic equipment onto the market.

Restrain:

• The availability of high-quality TB diagnostic services is sometimes constrained, especially in underdeveloped and isolated areas.

It can be difficult to diagnose latent TB infection, which occurs when a person has TB germs but does not exhibit any obvious symptoms. The price of TB diagnostic tests can be a considerable obstacle, particularly in areas with limited resources where affordability is a key factor.

Opportunity:

• There is an increasing demand for point-of-care TB diagnostic tests that can offer speedy and accurate results at the site of care.

• Continued innovation in TB diagnostic technology is necessary to address the limitations of present testing.

• Point-of-Care Platforms and TB Diagnostics Integration.

By combining TB diagnostics with existing or future point-of-care platforms, such as mobile health technology or portable molecular testing instruments, the accessibility and efficacy of TB diagnosis can be increased. These integrated platforms can improve disease surveillance and patient management by enabling real-time data collection, remote monitoring, and seamless system connections with healthcare systems.

Challenge:

• It can be difficult to gather and handle the right samples, including sputum specimens, for TB diagnosis.

The use of sophisticated TB diagnostic technology is hampered by resource shortages, including funding restrictions, laboratory capacity, and a lack of skilled workers.

Impact of covid-19:

In addition to outlining the key market trends, the Tuberculosis (TB) Diagnostics Market Research Reports go into great detail about the effects of the coronavirus. Insights, analysis, projections, and predictions on COVID-19's effect on the industry are provided in the report's research It is clear that the current crisis is fundamentally different from earlier recessions, given the scope of the pandemic's disruption. The sudden drop in demand and rising unemployment will alter the business climate. Businesses may forge new paths in this unsettling climate by embracing cutting-edge concepts like advancing towards localization, cash conservation, supply chain resilience, and innovation.

A recent study found that TB cases are present in 0.38 to 4.50% of COVID-19 patients. Experts and academics have proposed that tuberculosis amplifies the effects of COVID-19. Both illnesses have pulmonary complications, which is quite concerning in the COVID-19 pandemic.

Impact of Russia and Ukraine-War:

In the WHO European Region, Ukraine has one of the highest TB incidence rates and one of the highest rates of MDR-TB (multidrug-resistant TB). In 2020, 4,257 people with MDR-TB were reported in Ukraine, compared to 566 patients across the entire European Union and European Economic Area, according to the most recent WHO report. Up until recently, there were severe shortages of TB diagnoses and anti-TB medications in Ukraine. To improve the Product outcomes of MDR-TB patients in Ukraine, a number of significant control interventions have been put in place over the past five years, including the availability of Xpert MTB/Rif and Xpert MTB/XDR (Cepheid; Sunnyvale, CA, USA) and a steady supply of WHO-recommended medications.

Civilian infrastructure, including healthcare facilities, has been partially devastated after the military invasion by the Russian Federation on February 24, 2022. More than 9 million people, or one-fourth of Ukraine's population, will be displaced by the middle of 2022, with most of them having departed the nation. People have spent a lot of time in congested, poorly ventilated air raid shelters, which create the perfect environment for the spread of Mycobacterium tuberculosis. 4 It was believed that this military war would have an impact on the availability of TB diagnoses and Products.5 We conducted a point prevalence study on the accessibility of inpatient and outpatient care, diagnostics, and anti-TB medications to evaluate the effects of the conflict.

Market Segmentation:

By Type:

• Culture-Based Diagnostics

• Sputum Smear Microscopy

• Rapid Molecular Diagnostics

By End User:

• Hospitals

• Diagnostics

• Laboratories

REGIONAL COVERAGE:

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe

• Asia-Pacific

  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

• The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of the Middle East & Africa

• Latin America

  • Brazil

  • Argentina

  • Rest of Latin America

Regional Analysis:

North America:

Compared to other locations, North America has a relatively low TB burden. The healthcare systems in the US and Canada are well-established, and their laboratory infrastructure is state-of-the-art. The use of cutting-edge diagnostic technology and a focus on point-of-care testing are characteristics of this industry. The market for TB diagnostics in North America is expanding thanks to research and development initiatives, industrial and academic partnerships, and government programmes.

Asia Pacific:

Asia Pacific has the largest prevalence of TB in the world, with high-burden nations including India, China, and Indonesia. The enormous number of people affected by TB in this area, raising awareness, and government measures to manage the disease are what is driving the market. However, limitations include limited access to high-quality diagnostic services, a weak healthcare infrastructure, and problems with affordability. A variety of conventional and cutting-edge diagnostic techniques are used in the market, and efforts are being made to increase access to molecular diagnostics and point-of-care testing.

Get Customized Report as per Your Business Requirement - Request For Customized Report

Key Players:

The major key players are Akonni Biosystems Inc., Alere Inc., Par Pharmaceutical, Lionex GmbH, Creative Diagnostics, Abbott Laboratories, BioMerieux SA, Cepheid, Hologic Inc., F. Hoffmann-La Roche Ltd and other players are listed in the final reports.

Alere Inc-Company Financial Analysis

Recent Development:

In July 2020: Cepheid, a subsidiary of Danaher, launched the Xpert MTB/XDR Test in collaboration with the Foundation for Innovative New Diagnostics (FIND). The test can expand the drug-resistance TB profile in about 90 minutes.

In May 2021: F. Hoffmann-La Roche Ltd. teamed with GenMark Diagnostics. Hoffman F. Hoffmann-La Roche Ltd. finalised the acquisition of GenMark for almost USD 1.8 billion. Through the acquisition, F. Hoffmann-La Roche Ltd. wants to expand its molecular diagnostics portfolio with GenMark’s syndromic testing capabilities.